These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 6668067)

  • 21. Absorption, excretion, and clinical efficacy of moxalactam in pediatric patients.
    Fujii R
    Rev Infect Dis; 1982; 4 Suppl():S656-63. PubMed ID: 6218579
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of aztreonam in the treatment of serious infections due to multiresistant gram-negative organisms, including Pseudomonas aeruginosa.
    Scully BE; Neu HC
    Am J Med; 1985 Feb; 78(2):251-61. PubMed ID: 4038574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A double beta-lactam combination versus an aminoglycoside-containing regimen as empiric antibiotic therapy for febrile granulocytopenic cancer patients.
    De Jongh CA; Joshi JH; Thompson BW; Newman KA; Finley RS; Moody MR; Salvatore PC; Tenney JH; Drusano GL; Schimpff SC
    Am J Med; 1986 May; 80(5C):101-11. PubMed ID: 3521269
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical evaluation of moxalactam therapy.
    Venezio FR; Westenfelder GO; Cook FV; Williams JE; Carruthers M; Reisberg BE; Emmerman J; Phair JP
    J Antimicrob Chemother; 1982 Nov; 10(5):435-43. PubMed ID: 6217184
    [No Abstract]   [Full Text] [Related]  

  • 25. Penetration of moxalactam into the cerebrospinal fluid and its application in therapy of bacterial meningitis.
    Cheng DL; Shi FW; Liu YC; Liu CY
    Taiwan Yi Xue Hui Za Zhi; 1987 Jun; 86(6):634-8. PubMed ID: 3655708
    [No Abstract]   [Full Text] [Related]  

  • 26. Prospective evaluation of moxalactam therapy for gram-negative bacillary meningitis.
    Rahal JJ; Simberkoff MS; Landesman SH
    J Infect Dis; 1984 Apr; 149(4):562-7. PubMed ID: 6725990
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Moxalactam in serious infections: clinical, bacteriologic, and pharmacokinetic studies.
    Giamarellou H; Tsagarakis J; Daikos GK
    Rev Infect Dis; 1982; 4 Suppl():S629-38. PubMed ID: 6218576
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Moxalactam for the treatment of bacterial meningitis in children.
    Freedman JM; Hoffman SH; Scheld WM; Lynch MA; da Silva HR; Rocha H; Sande MA
    J Infect Dis; 1983 Nov; 148(5):886-91. PubMed ID: 6415181
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of lamoxactam in the treatment of severe bacterial infections.
    Bouza E; Martínez-Beltrán J; Rodríguez-Creixems M; Loza E; Pérez del Rio J; Guerrero A; Hospital JS
    Chemotherapy; 1983; 29(5):373-83. PubMed ID: 6617297
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Moxalactam for treatment of nosocomial infections.
    Winston DJ; Kurtz TO; Young LS; Busuttil RW
    Rev Infect Dis; 1982; 4 Suppl():S650-S655. PubMed ID: 6218578
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Moxalactam in the treatment of intraabdominal sepsis and other surgical infections.
    Busuttil RW; McGrattan MA; Winston DJ
    Rev Infect Dis; 1982; 4 Suppl():S676-82. PubMed ID: 6218582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enterococcal infections in patients treated with moxalactam.
    Moellering RC
    Rev Infect Dis; 1982; 4 Suppl():S708-11. PubMed ID: 6218588
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparative trial of moxalactam plus ticarcillin and clavulanic acid or piperacillin as empiric antibiotic therapy for febrile cancer patients.
    D'Olimpio JT; Miller M; Sheridan CA; Carlisle P; Wollner DI; McKitrick JC; Wiernik PH
    J Clin Pharmacol; 1987 Sep; 27(9):673-7. PubMed ID: 3316311
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical efficacy of moxalactam with emphasis on infections due to multidrug-resistant organisms in patients with renal insufficiency.
    Trager GM; Panwalker AP; Malow JB; Porembski PE; Ramirez CA; Zar FA
    Chemotherapy; 1981; 27(4):287-95. PubMed ID: 6454542
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of cefotaxime, a beta-lactamase stable cephalosporin, in the therapy of serious infections, including those due to multiresistant organisms.
    Francke EL; Neu HC
    Am J Med; 1981 Sep; 71(3):435-42. PubMed ID: 6269426
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Open study of ceftazidime in serious infections due to multiply-resistant bacteria.
    Pechère JC; Delisle R
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():181-8. PubMed ID: 6352619
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Moxalactam in the therapy of serious infections.
    Marier RL; Faro S; Sanders CV; Williams W; Derks F; Janney A; Aldridge K
    Antimicrob Agents Chemother; 1982 Apr; 21(4):650-4. PubMed ID: 6211140
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of moxalactam and gentamicin in the treatment of complicated urinary tract infections.
    Penn RG; Preheim LC; Sanders CC; Giger DK
    Antimicrob Agents Chemother; 1983 Oct; 24(4):494-9. PubMed ID: 6606393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized controlled trial of moxalactam versus clindamycin/tobramycin in the treatment of mixed anaerobic/aerobic infections.
    Joshi M; Fitzpatrick BJ; Warren JW; Caplan ES; Tenney JH
    Am Surg; 1986 Sep; 52(9):467-71. PubMed ID: 3530075
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Timentin versus moxalactam in the treatment of skin and soft tissue infections.
    Tan JS; File TM; Salstrom SJ
    Am J Med; 1985 Nov; 79(5B):130-3. PubMed ID: 4073079
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.